



GlaxoSmithKline Inc.  
7333 Mississauga Road  
Mississauga, Ontario  
L5N 6L4  
Tel.: 1-800-387-7374

**Any suspected adverse reaction can be reported to:**

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)  
Marketed Health Products Directorate

HEALTH CANADA

Address Locator: 0701C

OTTAWA, Ontario, K1A 0K9

Tel: (613) 957-0337 or Fax: (613) 957-0335

To report an Adverse Reaction, consumers and health professionals may call toll free:

Tel: 866 234-2345

Fax: 866 678-6789

[cadrmpp@hc-sc.gc.ca](mailto:cadrmpp@hc-sc.gc.ca)

The [AR Reporting Form](#) and the [AR Guidelines](#) can be found on the Health Canada web site or in *The Canadian Compendium of Pharmaceuticals and Specialties*.

[http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/form/ar-ei\\_form\\_e.html](http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/form/ar-ei_form_e.html)

[http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/guide/ar-ei\\_guide-ldir\\_e.html](http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/guide/ar-ei_guide-ldir_e.html)

**For other inquiries related to this communication, please contact Health Canada at:**

Marketed Health Products Directorate (MHPD)

E-mail: [mhpd\\_dpdc@hc-sc.gc.ca](mailto:mhpd_dpdc@hc-sc.gc.ca)

Tel: (613) 954-6522

Fax: (613) 952-7738

AVANDIA<sup>®</sup> and AVANDAMET<sup>®</sup> are registered trademarks, used under license by GlaxoSmithKline Inc.

AVANDARYL<sup>™</sup> is a trademark, used under license by GlaxoSmithKline Inc.

For media inquiries, please contact GSK Corporate Communications, (905) 819-3363.

References:

1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *New Engl J Med*. 2006;355:2427-2443.